SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Barton MB. Radiotherapy utilisation in New South Wales from 1996 to 1998. Australas Radiol. 2000; 44: 483484.
  • 2
    Denham JW. How do we bring an acceptable level of radiotherapy services to a dispersed population? Australas Radiol. 1995; 39: 171173.
  • 3
    Lote K, Moller T, Nordman E, et al. Resources and productivity in radiation oncology in Denmark, Finland, Iceland, Norway and Sweden during 1987. Acta Oncol. 1991; 30: 555561.
  • 4
    Mackillop WJ, Dixon P, Zhou Y, et al. Variations in the management and outcome of non-small cell lung cancer in Ontario. Radiother Oncol. 1994; 32: 105115.
  • 5
    Robertson G. An aid to planning cancer services in Scotland in the next decade. Prospects for radiation oncology, 2001 [monograph on line]. Available from URL: www.scotland.gov.uk [accessed July 2004].
  • 6
    Moller TR, Brorsson B, Ceberg J, et al. A prospective survey of radiotherapy practice 2001 in Sweden. Acta Oncol. 2003; 42: 387410.
  • 7
    Delaney G, Barton B, Jacob S. Estimation of an optimal radiotherapy utilization rate for breast cancer: a review of the evidence. Cancer. 2003; 98: 19771986.
  • 8
    Delaney G, Barton M, Jacob S, Jalaludin B. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol. 2003; 4: 120128.
  • 9
    Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for melanoma. A review of the evidence. Cancer. 2004; 100: 12931301.
  • 10
    Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gastrointestinal cancer: a review of the evidence. Cancer. 2004; 101: 657670.
  • 11
    Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecological cancer. Part I—cancer of the cervix, ovary, vagina and vulva. Cancer. 2004; 101: 671681.
  • 12
    Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecological cancer. Part II—cancer of the endometrium. Cancer. 2004; 101: 682692.
  • 13
    National Cancer Institute. CancerNet PDQ cancer information summaries: treatment of Hodgkin's disease. Available from URL: http://nci.nih.gov [accessed July 2004].
  • 14
    National Cancer Institute. CancerNet PDQ cancer information summaries: treatment of non-Hodgkin's lymphoma. Available from URL: http://nci.nih.gov [accessed July 2004].
  • 15
    National Cancer Institute. CancerNet PDQ cancer information summaries: treatment of Mycosis Fungoides. Available from URL: http://nci.nih.gov [accessed July 2004].
  • 16
    National Comprehensive Cancer Network. Guidelines on Hodgkin's disease. Available from URL: www.nccn.org [accessed July 2004].
  • 17
    National Comprehensive Cancer Network. Guidelines on non-Hodgkin's lymphoma. Available from URL: www.nccn.org [accessed July 2004].
  • 18
    British Committee for Standards in Haematology. Guidelines for non-Hodgkin's lymphoma [draft]. Monograph on line. Available from URL: www.bcshguidelines.com [accessed July 2004].
  • 19
    European Society of Medical Oncology. Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin's disease. Ann Oncol. 2001; 12: 12131214.
  • 20
    European Society of Medical Oncology. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma. Ann Oncol. 2001; 12: 12091210.
  • 21
    European Society of Medical Oncology. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of relapsed large cell non-Hodgkin's lymphoma. Ann Oncol. 2001; 12: 12111212.
  • 22
    National Health and Medical Research Council. Guide to the development, implementation and evaluation of clinical practice guidelines. Appendix B, 56. Canberra: National Health and Medical Research Council, 1998.
  • 23
    Congdon P. Bayesian statistical modelling. New York: John Wiley & Sons, 2002.
  • 24
    Luke C, Chapman P, Priest K, Roder D. Use of radiotherapy in the primary treatment of cancer in South Australia. Australas Radiol. 2003; 47: 161167.
  • 25
    South Australian Cancer Registry. Epidemiology of cancer in South Australia (cancer series no. 22). Adelaide: South Australian Cancer Registry, 2000.
  • 26
    National Cancer Institute (Cancer Statistics Branch). SEER*Stat 5.0. Surveillance, Epidemiology and End Results cancer incidence public-use database, 1973–2000. Bethesda: U.S. Department of Health and Human Services, 2002.
  • 27
    Northern and Yorkshire Cancer Registry and Information Service (NYCRIS). Northern and Yorkshire Cancer Networks. A report on incidence and management for the main sites of cancer 1999. Available from URL: http://www.nycris.org.uk/ [accessed November Day 25, 2003].
  • 28
    Glass AG, Karnell LH, Menck HR. The National Cancer Database report on non-Hodgkin&;s lymphoma. Cancer. 1997; 80: 23112320.
  • 29
    Kennedy BJ, Fremgen AM, Menck HR, et al. The National Cancer Database report on Hodgkin's disease for 1985–1989 and 1990–1994. Cancer. 1998; 83: 10411047.
  • 30
    Australian Institute of Health and Welfare (AIHW). Cancer incidence data: cancer age-standardised database (1997). Canberra: Australian Institute of Health and Welfare, 2001.
  • 31
    Glimelius B, Enblad G, Kalkner M, et al. Treatment of Hodgkin's disease: the Swedish National Care Programme experience. Leuk Lymphoma. 1996; 21: 7178.
  • 32
    Taylor PRA, Angus B, Owen JP, et al on behalf of the Northern Region Lymphoma Group. Hodgkin's disease: a population-adjusted clinical epidemiological study (PACE) of management at presentation. Q J Med. 1998; 91: 131139.
  • 33
    Amini RM, Enblad G, Gustavsson A, et al. Treatment outcomes in patients younger than 60 years with advanced stages (IIB–IV) of Hodgkin's disease: the Swedish National Health Care Programme experience. Eur J Haematol. 2000; 65: 379389.
  • 34
    Amini RM, Glimelius B, Gustavsson A, et al. A population based study of the outcome for patients with first relapse of Hodgkin's lymphoma. Eur J Haematol. 2002; 68: 225232.
  • 35
    Linch D, Winfield D, Goldstone AH. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993; 341: 10511054.
  • 36
    Young RC, Canellos GP, Chabner BA, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Cancer. 1978; 42: 10011007.
  • 37
    United States Department of Health and Human Services. SEER cancer incidence database, 1973–1997. Washington, DC: United States Department of Health and Human Services, 2000.
  • 38
    Armitage JO, Weisenburger DD, for the NHL Classification Project. New approach to classifying NHL: clinical features of the major histologic subtypes. J Clin Oncol. 1998; 16: 27802795.
  • 39
    The NHL Classification Project. Effect of age on characteristics and clinical behaviour of non-Hodgkin's lymphoma patients. Ann Oncol. 1997; 8: 973978.
  • 40
    Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one-third of 158 patients analysed. Blood. 2000; 95: 802806.
  • 41
    Ruskone-Fourmestraux A, Lavergne A, Aergerter PH, et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut. 2001; 48: 297303.
  • 42
    Stolte M, Bayerdorffer E, Morgner A, et al. Helicobacter and gastric MALT lymphoma. Gut. 2002; 50: 1924.
  • 43
    Fischbach W, Dragosics B, Kolve-Goebeler ME, et al. Primary gastric B-cell lymphoma: results of a prospective multicenter study. Gastroenterology. 2000; 119: 11911202.
  • 44
    Thiede C, Wundisch T, Neubauer B. Eradication of Helicobacter pylori and stability of emissions in low-grade gastric B-cell lymphomas of the mucosa-associated lymphoid tissue: results of an ongoing multicenter trial. Cancer Res. 2000; 156: 125133.
  • 45
    Neubauer A, Thiede C, Morgner A, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst. 1997; 89: 13501355.
  • 46
    Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med. 1984; 311: 14711475.
  • 47
    Maartense E, Hermans J, Kluin-Nelemans JC, et al. Elderly patients with non-Hodgkin's lymphoma: population based results in the Netherlands. Ann Oncol. 1998; 9: 12191227.
  • 48
    Federico M, Vitolo U, Zinzani PL, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Blood. 2000; 95: 783.
  • 49
    Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single agent versus combination chemotherapy in indolent follicular lymphomas: a study of the Cancer and Leukaemia Group B. J Clin Oncol. 2003; 21: 515.
  • 50
    Johnstone PWM, Rohatiner AZS, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single centre. J Clin Oncol. 1995; 13: 140147.
  • 51
    Montoto S, Lopez-Guillermo A, Ferrer A, et al. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Ann Oncol. 2002; 13: 523530.
  • 52
    Portlock CS, Rosenberg SA. No initial therapy for Stage III and IV non-Hodgkin's lymphoma of favourable histologic types. Ann Intern Med. 1979; 90: 1013.
  • 53
    Phillip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333: 15401545.
  • 54
    Green SB, Byar DP, Lamberg SI. Prognostic variables in Mycosis Fungoides. Cancer. 1981; 47: 26712677.
  • 55
    Herrmann JJ, Roenigk HH, Hurria A, et al. Treatment of Mycosis Fungoides with photochemotherapy (PUVA): long term follow-up. J Am Acad Dermatol. 1995; 33: 234242.
  • 56
    Featherstone C, Delaney G, Jacob S, Barton M. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence. Part II—leukemia and myeloma. Cancer. 2004: 103: 393401.